Evidence summaries for obesity and weight management, including lifestyle trials, pharmacotherapy, bariatric/metabolic outcomes, cardiometabolic risk, and long-term safety.
A SURMOUNT-1 analysis finds tirzepatide improves insulin sensitivity (mostly via weight loss) and beta-cell function (mostly drug-driven) in obesity without diabetes. PICO summary and commentary.
A SURMOUNT-1 analysis finds 90% of early non-responders to tirzepatide still reached 5% weight loss by week 72, supporting extending treatment. PICO summary and commentary.
First-in-human phase 1 trial finds the oral GLP-1/amylin co-agonist amycretin safe and well tolerated with dose-dependent gastrointestinal effects; weight and glucose changes were exploratory only. PICO summary and expert commentary.
An early-phase trial reports large but exploratory weight-loss signals for subcutaneous amycretin in overweight and obesity, with safety as the primary focus. PICO summary and expert commentary.
An Eli Lilly-sponsored indirect treatment comparison links tirzepatide 10 and 15 mg to greater weight, BMI and HbA1c reductions than semaglutide 2.4 mg in patients with type 2 diabetes, with no head-to-head trial. PICO summary and expert commentary.
A phase 2b trial finds oral danuglipron produces significant weight loss in obesity but with high discontinuation from gastrointestinal side effects. PICO summary and commentary.
An exploratory analysis of two Phase 2 trials found that oral orforglipron produced placebo-adjusted reductions in cardiovascular risk biomarkers, not clinical events, in adults with type 2 diabetes or obesity. PICO summary and expert commentary.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
